Scarica l'app Stockscreener
102.20
1.13%
1.14
Dopo l'orario di chiusura:
102.20
Precedente Chiudi:
$101.06
Aprire:
$99.88
Volume 24 ore:
422.88K
Relative Volume:
0.57
Capitalizzazione di mercato:
$7.04B
Reddito:
$217.17M
Utile/perdita netta:
$-202.68M
Rapporto P/E:
-44.38
EPS:
-2.3028
Flusso di cassa netto:
$-156.63M
1 W Prestazione:
-2.56%
1M Prestazione:
-11.50%
6M Prestazione:
+9.88%
1 anno Prestazione:
+1.92%
Intervallo 1D:
$99.88
$102.89
Intervallo di 1 settimana:
$99.41
$105.71
Portata 52W:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
102.20 | 6.96B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-11-25 | Iniziato | Citigroup | Buy |
| 2025-11-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - The Manila Times
French children showed lower body-size scores on a rare-obesity drug - Stock Titan
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 36.45% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
An AI drug specialist zeroes in on rare forms of obesity - BioPharma Dive
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth - AD HOC NEWS
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$6.62 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) CFO sells 62,774 shares in planned trade - Stock Titan
Rhythm (NASDAQ: RYTM) officer files Rule 144 stock sale notice - Stock Titan
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Rhythm Pharmaceuticals (RYTM): Investor Outlook on a 30.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc. (RYTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
RHYTHM PHARMACEUTICALS, INC. : DEUTSCHE BANK INITIATES COVERAGE WITH HOLD RATING AND TARGET PRICE $120 - webull.com
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story - Sahm
Rhythm Pharmaceuticals Gains Japan Approval For IMCIVREE In Hypothalamic Obesity - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run - Yahoo Finance
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies - DirectorsTalk Interviews
*Rhythm Pharmaceuticals: Commercial Launch in Japan Expected by End of 2026, Pending Final Pricing Determination >RYTM - webull.com
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can - Yahoo Finance
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock - Investing.com
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com - Investing.com India
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock - Investing.com
Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan - Stock Titan
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts - NewsBreak: Local News & Alerts
Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 22.56% Potential Upside on Robust Analyst Confidence - DirectorsTalk Interviews
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV - TradingView
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock - Investing.com
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):